Description
The world’s only comprehensive, publicly available database of Cell & Gene Therapy CDMOs that is quality-controlled by human analysts.
This week only, you can claim this Global Database and its 7-Page Companion Briefing for 50% off.
The 2026-27 edition of the BioInformant database reflects a year of heavy consolidation in the cell and gene therapy contract manufacturing sector. We removed 20 companies that have closed, merged or been absorbed into other organizations, and added 6 new entries, including newly formed CDMOs such as Rose BioSolutions, Kincellis Advanced Therapies and 3PBIOVIAN.
The database profiles well over a hundred organizations, and acquisitions, divestitures and rebrands from the past year are reflected throughout. This edition also adds more detail on each company, giving you a fuller picture of who is operating in the market today and who owns them.
If you want a full picture of the aggressive consolidation happening within this industry, read on. It’s an exciting time for CGT manufacturing, but also a highly competitive one!
CGT CDMO Industry Activity and Consolidation
To understand the changes behind this year’s update, here is a look at the major milestones that have shaped the cell and gene therapy CDMO sector in recent years.
In 2019, Anemocyte introduced itself as the first BMO (Biotech Manufacturing Organization) in the field of cell and gene therapies. In addition to building 2000 sq. meters of GMP and GMP-compliant facilities for the production of ATMPs, its FLYn’ICE project is using drones equipped with cryogenic pods to achieve temperature controlled transit of cell and gene therapies.
Also in 2019, there were hefty M&A deals inked within the cell and gene therapy CDMO sector as well. For example, industry behemoth Thermo Fisher Scientific snagged Brammer Bio for an astonishing $1.7B (2019), while Catalent acquired Paragon Bioservices for an impressive $1.2B (2019) and MaSTherCell for $315 million (2020).
In 2020, FUJIFILM Cellular Dynamics opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
In 2021, Charles River Laboratories (CRL) acquired Cognate BioServices for a hefty price tag of $875 million. Also in 2021, Helixmith, a biotech company with an extensive gene therapy pipeline and a CAR-T program targeting solid tumors, expanded into CDMO services for early-stage CAR-T developers.
In 2022, ThermoGenesis launched CDMO services with expertise in CAR-T cells, T cell receptor (TCR), tumor-infiltrating leukocytes (TILs), natural killer cells (NKs), iPSCs, and MSCs. Also in 2022, RoslinCT, a cell and gene therapy CDMO based in the UK, and Lykan Bioscience, a CDMO focused on cellular therapeutics in Hopkinton, MA, merged to form an international CDMO specializing in advanced therapeutics—with a specialty in gene editing and iPSC capabilities.
In 2023, Ascend Gene & Cell Therapies raised an impressive $132.5M to launch itself as a CDMO specializing in AAV-based gene therapies. Similarly, Esco Aster is a global CDMO that is supporting the rapidly emerging field of EVs, producing both regenerative medical-grade naïve extracellular vesicles (MNEVs) and Continuously Engineered Exosomes/Extracellular Vesicles (CEEVs).
In late 2023, Bayer opened a $250M cell therapy manufacturing facility to advance regenerative medicines on a global scale. Around the same time, Ajinomoto Co. acquired CDMO Forge Biologics for an astounding $620 million to enhance its Bio-Pharma Services business. In 2024, EXO Biologics launched its wholly owned subsidiary, ExoXpert**™**, as a CDMO specializing in exosomes. ExoXpert offers a MSC-based exosome manufacturing platform used in European clinical trials.
In February 2024, 3P Biopharmaceuticals and Biovian combined to form 3PBIOVIAN, a pan-European CDMO with viral vector, plasmid and cell therapy capabilities. In 2024, Novo Holdings acquired the global CDMO Catalent for a staggering $16.5 billion in enterprise value, while Avid Bioservices was snagged by private equity companies in early 2025 in an all-cash transaction worth a breathtaking $1.1 billion.
Hitachi Chemical Advanced Therapeutics Solutions (HCATS), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. Regenerative Medicine combined to operate under the joint name of Minaris Regenerative Medicine, which subsequently merged with WuXi Advanced Therapies in early 2025 to become Minaris Advanced Therapies.
The pace of change continued through 2025 and 2026. In March 2025, BioCentriq rebranded as Made Scientific, and in April 2025 Artis BioSolutions launched with its acquisition of Landmark Bio, which it has since unified with Syngoi Technologies under the Artis brand. In October 2025, Mytos, a London-based company, launched an automated CDMO for stem cell-derived therapies.
In May 2026, Charles River divested its cell and gene therapy CDMO and Cell Solutions businesses, including Cognate, Cobra Biologics and Vigene Biosciences, to GI Partners, which launched them as Rose BioSolutions, a new independent CDMO focused exclusively on cell and gene therapy.
In September 2026, Cellipont Bioservices and Kincell Bio merged to form Kincellis Advanced Therapies.
Database of Cell and Gene Therapy CDMOs
When you claim this database, you can immediately know the identities of all known cell and gene therapy CDMOs worldwide. It will also get you instantly up to speed on the aggressive consolidation happening within this industry right now and who’s buying whom.
It takes our analysts a vast amount of research to uncover these cell and gene therapy (CGT) CDMOs from across the globe and requires the translation of websites across numerous languages. Thankfully, we have a talented, multilingual team who is up to the task.
As you can imagine, the quality of this database would not be possible without the past two decades (20+ years) of following this industry and developing proprietary datasets (to which AI does not have access).
Most importantly, this database is quality controlled by human analysts, because as the old saying goes, “The most expensive information is wrong information.”
You don’t have the time to do the research or worry about the accuracy of AI results, when these tools don’t understand the nuances of this rapidly evolving industry and all too often present erroneous information as “facts”.
If you want immediate and actionable insights from a trusted, U.S. based provider that specializes exclusively in cell therapy market insights, then this database is for you.
If you are a cell therapy developer, you can use this database to identify potential manufacturing partners. If you are a contract manufacturer, you can use it to identify the depth and breadth of your market competition.
The database features detailed, searchable and sortable insights, including:
- Name of Company
- Year Founded
- Founder(s)
- Current CEO
- Parent/Owner
- Type of CMO/CDMO
- City and State
- Country
- Company Website
- Company Phone
- Email Contact
- Company LinkedIn
- Primary Modalities and Services
- Description of Cell and Gene Therapy CDMO Services
Use it to:
- Compare companies capable of manufacturing your cell or gene therapy product
- Identify all known market competitors within the cell therapy CDMO industry
- Identify new market entrants offering CDMO services
- Spot countries with a high number of cell and gene therapy CDMOs (“geographic hotspots”)
- Identify companies that specialize in the production of specific types of CGT products (“niche” CDMOs)
Deliverables (Provided Instantly):
-
Global CGT CDMO Database provided as an Excel File, featuring 124 industry competitors. (See Sample.)
-
A Companion Industry Briefing (PDF): Featuring a visual summary of the past two years of cell and gene therapy CDMO consolidation, a 2019–2026 timeline of launches/deals/closures, the key themes behind this year’s changes, profiles of the six new entries, and a reference table showing where each of the 20 removed companies can now be found. (See Sample.)
